In both the human fibrosarcoma mouse model (Fig 4B) and colorectal cancer mouse model (Fig 4C), intraperitoneal injection of either KY-NAb-GDF15 antibody or the control antibody Ponsegromab (1 mg/kg and 10 mg/kg) yielded nearly identical results based on the percentage change in body weight per day, while other control groups did not exhibit improvement in the decline in body weight of mice. Here, GDF15 is linked to fibrosarcoma.